December 7 at 1:30 pm PT/4:30 pm ET

Details of inequities and lack of diversity in clinical research have been revealed with the COVID-19 pandemic. Under-representation of diverse groups in clinical trials, mistrust in research, the lack of diversity across the healthcare workforce: Each contributes significantly to the persistence of these inequities. We need to define the respective roles of science, policy, and digital health technologies in making recruitment and retention in clinical trials more equitable and inclusive—particularly now, for COVID-19 treatments and vaccines. There is a critical need to integrate the patient perspective while ensuring that trials are conducted in a more equitable way. Engaging with stakeholders, such as academic researchers, industry, community leaders, and patient advocates, would help to fill the gaps. In this session, panelists will draw from a range of perspectives to focus on disrupting outdated systems for how research is pursued and conducted.
 

Welcoming Remarks

Yasmeen Long
Director, FasterCures, Milken Institute
 

Opening Remarks

Terris King
Pastor, Liberty Grace Church of God; CEO, King Enterprise Group
 

Speakers

Richardae Araojo
Associate Commissioner for Minority Health, US Food and Drug Administration

Quita Highsmith
Vice President and Chief Diversity Officer, Genentech, a member of the Roche Group

Carol Horowitz
Director, Institute for Health Equity Research, Mount Sinai

Jeanne Regnante
Chief Health Equity and Diversity Officer, LUNGevity Foundation

Deneen Vojta
Executive Vice President, Global Research and Development, UnitedHealth Group; Chief Physician Executive, Optum Labs
 

Moderator

Joseph Williams
Senior News Editor, US News & World Report